The Latest Breaking News from Sarepta

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a strategic restructuring and cost-cutting measures.

After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names.

The U.S. Food and Drug Administration has approved the first gene therapy to treat a deadly form of muscular dystrophy

The FDA is considering greenlighting the experimental treatment under its accelerated approvals program. Some critics point out the therapy isn't yet proven to work and may be costly.

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Here's a roundup of top developments in the biotech space over the last 24 hours:

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ: SRPT) lead candidate to treat patients with Duchenne muscular dystrophy.

Sarepta Therapeutics Inc (NASDAQ: SRPT) will pay GenEdit up to